Supplied formTwo-component peptide mixture; each sequence, modification and counterion requires independent identification
Lead time10–18 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
No sleep, recovery, lean-mass, body-composition, anti-aging or metabolic benefit has been established for this blend
Scientifically supportable uses include two-analyte identification and quantitation, blend homogeneity and stability studies, and controlled in vitro comparison of GHRH-receptor and GHSR1a signalling with each single component as a control.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
Confirm per batch COA
Formula
Not applicable — mixture or multi-component material
Molecular weight
Component-specific; no single molecular weight
Appearance
Lot-specific lyophilized solid; confirm whether the quoted material is co-lyophilized or separately blended
Purity
Component-specific, lot-released results required; one aggregate percentage is insufficient · target, verify batch COA
Storage
Store and ship according to the lot-specific COA and validated data for the exact two-component formulation. Separate-component stability does not establish co-lyophilized or reconstituted blend stability. Require component recovery, ratio retention, adsorption, degradation and freeze-thaw data for the specified diluent, container, concentration, light and temperature conditions.
MOQ
1 kit (10 vials) per SKU
Lead time
10–18 days
Qualification matrix
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about CJC 5mg + IPA 5mg
This item is a vendor-defined mixture of a non-DAC CJC-1295-related GHRH analogue and ipamorelin, a growth-hormone secretagogue receptor agonist. Receptor convergence makes combination research plausible, but the exact blend lacks direct controlled clinical validation. The best human ipamorelin PK/PD study used a 15-minute intravenous infusion, while the well-known CJC-1295 human half-life study used the DAC-conjugated molecule. Neither study validates a no-DAC co-lyophilized vial, its ratio, subcutaneous use or claimed outcomes.
No clinical indication applies
Appropriate research contexts include orthogonal component identification, quantitative ratio and vial-uniformity testing, forced degradation, adsorption and compatibility studies, and controlled in vitro GHRHR/GHSR1a signalling experiments
Human GH deficiency, body composition, recovery, sleep and anti-aging are not validated indications for the blend.
Mechanism context
The question the literature is testing
The non-DAC CJC-1295-related component is intended to activate the GHRH receptor, while ipamorelin activates GHSR1a. Distinct signalling pathways can converge on pituitary GH release, but the magnitude, timing, receptor desensitization and downstream IGF-1 response of this exact mixture have not been established. Preclinical selectivity findings for ipamorelin and clinical results from other GHRH/GHRP combinations do not prove synergy for this pair.
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
There is no combination-specific clinical safety, immunogenicity, toxicology or long-term exposure dataset
The 2014 ipamorelin postoperative-ileus trial did not meet its primary efficacy endpoint, and its intravenous formulation cannot validate a commercial blend
FDA's 2024 PCAC reviews proposed that ipamorelin-related and CJC-1295-related bulk substances not be added to the 503A Bulks List; advisory recommendations are not product approvals
FDA's current safety page separately identifies immunogenicity, aggregation, peptide-impurity, API-characterization and serious-adverse-event concerns for the related components; these signals must not be attributed to or dismissed for the exact blend without data
Both CJC-1295 and ipamorelin are prohibited at all times under WADA's 2026 S2.2.4 category
This material is not for human or veterinary administration.
Interactions reported in the literature
No validated stacking or combination protocol exists
Claims of compatibility or synergy with MK-677, BPC-157, insulin, thyroid drugs, corticosteroids, HGH or other secretagogues are unsupported for this material and may confound GH-axis and analytical endpoints
Laboratory mixtures require compound-specific compatibility and interference testing.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
CJC 5mg + IPA 5mg batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Third-party reports for CJC 5mg + IPA 5mg
Reports from Qorix (tjqxgd.com), a third-party analytical laboratory in Tianjin, China: HPLC purity and MS identity of the sample tested.
Laboratory: Third-party laboratoryTests: HPLC purity · MS identity
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Ask for the current packet, not a generic certificate
Appearance or a perceived physiological response cannot establish authenticity
Require independent high-resolution intact mass and sequence-confirming MS/MS or peptide mapping for both components; chromatographic separation and component-specific purity; net peptide content confirming the stated 5 mg plus 5 mg amount and 1:1 ratio; blend homogeneity and vial-to-vial uniformity; counterion, water, residual solvent, impurity and degradant profiles; and formulation-specific stability
Explicitly distinguish no-DAC from DAC-conjugated CJC-1295
A single aggregate HPLC purity value is insufficient.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
CJCIPA51010 mg10 vials
Handling
Plan storage before the parcel arrives
Store and ship according to the lot-specific COA and validated data for the exact two-component formulation. Separate-component stability does not establish co-lyophilized or reconstituted blend stability. Require component recovery, ratio retention, adsorption, degradation and freeze-thaw data for the specified diluent, container, concentration, light and temperature conditions.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
Raun 1998 is preclinical ipamorelin pharmacology. Gobburu 1999 is human intravenous ipamorelin PK/PD. Teichman 2006 evaluates DAC-conjugated CJC-1295, not the no-DAC component. Beck 2014 evaluates intravenous ipamorelin for postoperative ileus and did not show a significant primary-endpoint benefit. Broader secretagogue reviews and studies using sermorelin, GHRP-2 or GHRP-6 are indirect evidence. FDA's 2024 PCAC materials, current compounding-safety page and the 2026 WADA list provide regulatory, safety and anti-doping context. No cited source validates this exact blend.
01
Ipamorelin, the first selective growth hormone secretagogue
European Journal of Endocrinology · 1998 · peer-reviewed original research (preclinical pharmacology)
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
The Journal of Clinical Endocrinology & Metabolism · 2006 · peer-reviewed original research (randomized, placebo-controlled clinical trials)
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
International Journal of Colorectal Disease · 2014 · peer-reviewed original research (Phase 2 randomized controlled trial)
What evidence supports the CJC-1295 no-DAC plus ipamorelin blend?+
The two components act at different GH-axis receptors, so a combined laboratory effect is mechanistically plausible. However, no qualifying controlled clinical trial of this exact no-DAC CJC-1295 plus ipamorelin mixture was identified. Quantitative claims such as a 4-5-fold larger GH pulse are not established for this product. Evidence from ipamorelin alone, DAC-conjugated CJC-1295, or other GHRH/GHRP pairs must remain clearly separated.
Can CJC-1295 no DAC be substituted with sermorelin, tesamorelin or DAC-conjugated CJC-1295?+
No automatic substitution is valid. These are different molecular entities with different sequences or modifications, pharmacokinetics, regulatory contexts and analytical specifications. A new component changes the mixture identity, ratio, stability and assay interpretation. Any comparison requires separate reference standards and a new validated experimental design.
What presentation and release evidence should a buyer request?+
Confirm whether the quote covers a finished co-lyophilized vial, a post-manufacture blend or two separate components. Request starting-material COAs plus finished-product results for both identities, component-specific purity and content, the stated 5 mg + 5 mg basis, ratio and vial uniformity, counterions, degradants and formulation-specific stability. The SKU label alone does not prove co-lyophilization, a 1:1 released ratio or blend stability.
